Phase II/III study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: NCIC CTG OV.21

Current Oncology

Volumn 18, Issue 2, 2011, Pages 84-90

  Mackay, H J ^a   Provencheur, D ^b   Heywood, M ^c   Tu, D ^d   Eisenhauer, E A ^d   Oza, A M ^a   Meyer, R ^d  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d Queen's Cancer Research Institute   (Canada)

Author keywords

Epithelial ovarian cancer; Intraperitoneal chemotherapy; NCIC CTG OV.21; Neoadjuvant chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; DRUG SAFETY; EXPERIMENTAL DESIGN; FEASIBILITY STUDY; HEALTH ECONOMICS; HUMAN; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; TREATMENT DURATION;

EID: 79955391315     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v18i2.725     Document Type: Article

References (32)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-2529.
3. Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978;62:1-11.
4. Howell SB, Pfeifle CL, Wung WE, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982;97:845-851.
5. Armstrong D, Bundy B, Wenzel L, et al. Phase iii randomized trial of intravenous cisplatin and paclitaxel versus an intensive regimen of intravenous paclitaxel, intraperitoneal cisplatin, and intraperitoneal paclitaxel in stage iii ovarian cancer: a Gynecologic Oncology Group study. N Engl J Med 2006;354:34-43.
6. Kirmani S, Braly PS, McClay EF, et al. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol Oncol 1994;54:338-344.
7. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage iii ovarian cancer. N Engl J Med 1996;335:1950-1955.
8. Polyzos A, Tasvaris N, Kosmas C, et al. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage iii ovarian cancer. Oncology 1999;56:291-296.
9. Gadducci A, Carnini F, Chiara S, et al. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologica Nord-Ovest. Gynecol Oncol 2000;76:157-162.
10. Markman M, Bundy BN, Alberts DS, et al. Phase iii trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage iii ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:1001-1007.
11. Yen MS, Juang CM, Lai CR, Chao GC, Ng HT, Yuan CC. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage iii optimally cytoreduced epithelial ovarian cancer. Int J Gynecol Obstet 2001;72:55-60.
12. United States, National Institutes of Health, National Cancer Institute (nci). nci Clinical Announcement: Intraperitoneal Chemotherapy for Ovarian Cancer. Bethesda, MD: nci; 2006. [Available online at: www.ctep.cancer.gov/highlights/docs/clin_annc_010506.pdf; cited December 17, 2010]
13. Gore M, Du Bois A, Vergote I. Intraperitoneal chemotherapy in ovarian cancer remains experimental. J Clin Oncol 2006;24:4528-4530.
14. Chambers JT, Chambers SK, Voynick IM, Schwartz PE. Neoadjuvant chemotherapy in stage x ovarian carcinoma. Gynecol Oncol 1990;37:327-331.
15. Ansquer Y, Leblanc E, Clough K, et al. Neoadjuvant chemotherapy for unresectable ovarian cancer: a French multicenter study. Cancer 2001;9:2329-2334.
16. Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI, Thiel RP. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol 1999;72:93-99.
17. Vergote I, Tropé CG, Amant F, et al. eortc-gcg/ncic-ctg randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage iiic-iv ovarian, fallopian tube and peritoneal cancer [abstract 2008_1767]. Plenary presentation at the 12th Biennial Meeting International Gynecologic Cancer Society; Bangkok, Thailand; October 25-28, 2008. [Available online at: www.igcs.org/Abstract/meeting_2008_1767.html; cited January 11, 2010]
18. Steed H, Oza A, Murphy J, et al. A retrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer. Int J Gynecol Cancer 2006;16:47-53.
19. McCluggage WG, Lyness RW, Atkinson RJ, et al. Morphological effects of chemotherapy on ovarian carcinoma. Am J Clin Pathol 2002;55:27-31.
20. Vergote I, Van Gorp T, Amant F, Neven P, Berteloot P. Neoadjuvant chemotherapy for ovarian cancer. Oncology 2005;19:1615-1622.
21. Eisenhauer EA, ten Bokkel Huinink W, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12:2654-2666.
22. Chin S, Pinto V, Rosen B, et al. Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma. Gynecol Oncol 2009;112:450-454.
23. Swenerton K, Jeffry J, Stuart G, et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1992;10:718-726.
24. Isonishi S, Pasuda M, Takahashi F, et al. Randomized phase iii trial of conventional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology [abstract 5506]. J Clin Oncol 2008;26. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31152; cited December 17, 2010]
25. Rose PG, Smrekar M, Fusco N. A phase ii trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma. Gynecol Oncol 2005;96:296-300.
26. Yumuk PF, Turhal NS, Gumus M, et al. Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage iii-iv) non-small cell lung cancer. BMC Cancer 2005;5:10.
27. Paul N, Pater J, Whitehead M, Sadura A. Methods of toxicity data collection and evaluation of the relative effectiveness of the case resort flow sheet, the patient symptom diary, and the quality of life questionnaire. Control Clin Trials 1991;12:648-655.
28. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.
29. Groenvold M, Klee MC, Sprangers MA, Aaronson NK. Validation of the eortc QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. J Clin Epidemiol 1997;50:441-450.
30. Cull A, Howat S, Greimel E, et al. Development of a European Organisation for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report. Eur J Cancer 2001;37:47-53.
31. Greimel E, Bottomley A, Cull A, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer 2003;39:1402-1408.
32. Calhoun EA, Welshman EE, Chang CH, et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-NTX) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 2003;13:741-748.